PPB recalls cancer drug Flurasted 500 (5-Fluorouracil) Injection, Batch No. HHP24017
All healthcare practitioners and dispensing pharmacies directed to immediately stop the use and sale of the batch.
The Ministry of Health on Thursday issued a notice recalling a cancer drug previously used for injection purposes.
The Pharmacy and Poisons Board (PPB) directed all healthcare practitioners and dispensing pharmacies to immediately stop the use and sale of Flurasted 500 (5-Fluorouracil) Injection.
More To Read
- Man sues over cancer deaths, seeks ban on toxic chemicals, stronger health protections
- Oesophageal cancer cases rise in Wajir as patients face delayed diagnosis
- Staffing shortage at National Cancer Institute puts strain on treatment services
- Government orders nationwide removal of asbestos, property owners to bear costs
- Is your non-stick pot putting your family at risk? Understanding Teflon and safer alternatives
- Single-dose HPV vaccine beneficial for children between 9 and 14 years
"The Pharmacy and Poisons Board ("the Board") orders the quarantine of Flurasted 500 (5-Fluorouracil) Injection, Batch No. HHP24017, manufactured by Halsted Pharma Private Limited, India," the Board stated.
The cancer drug, commonly used in chemotherapy to treat cancers such as colon, breast, and stomach cancer, has been flagged for potential quality concerns.
The Board has directed health practitioners and pharmaceutical outlets to immediately stop using, distributing, or selling the affected batch while it works to remove it from circulation.
"In light of this, the Board advises all pharmaceutical outlets, healthcare facilities, healthcare professionals, and members of the public to immediately quarantine the product batch and stop the further distribution, sale, issuance, or use of the affected batch," the notice added.
The board clarified that manufacturers occasionally recall specific batch numbers, so patients should be aware of this.
The Board has also urged the public to report any suspected cases of substandard drugs to the nearest health facility for immediate action.
The PPB issued another recall on November 22, 2024, involving two nasal drops manufactured by Laboratory and Allied Ltd in Kenya, Efinox 1% w/v (Batch No. 82979) and Efinox 0.5% w/v (Batch No. 82978).
"The Pharmacy and Poisons Board has mandated the recall of Efinox 1% w/v Batch No. 82979 and Efinox 0.5% w/v Batch No. 82978 manufactured by Laboratory and Allied Ltd, Kenya," the statement read.
A mix-up in labelling and packaging led to differences in the potency of the drugs, prompting the earlier recall.
Top Stories Today
- Explosions heard in Sudanese city of Port Sudan, witness says
- TSC declares over 2,000 teaching posts vacant in bid to fill staffing gaps
- Taxpayers to fund Sh2.3 billion State House, lodges facelift
- AU, IGAD step up efforts to revive South Sudan's stalled peace process
- E-mobility drive: Kenya Power to install 45 EV charging stations
- Papal conclave: All cardinals who will elect new pope arrive in Rome
- Mombasa, Kilifi and Kwale among regions to be affected by power blackouts
- Sudan's RSF launches second drone attack in Port Sudan
- National campaign launched to tackle GBV and femicide
- Bobi Wine aide brought to court limping, charged and remanded
- Congo, Rwanda submit draft peace proposal, Trump adviser says
- Inside Eastleigh SIM-swap heist: Sh3.2m stolen via fake accounts, IDs
- High Court halts order for Nyashinski to reveal Tecno deal in copyright row
- ICJ Kenya hails ruling declaring Worldcoin’s data collection unlawful
- Ministry sounds alarm as youth drug abuse spikes in 10 counties
- South Sudan invites AU and IGAD chiefs for crisis talks
- Pope Francis's popemobile set to become health clinic for Gaza children
- Millers increase unga prices as maize supply tightens
- Court to rule on halt of prison recruitments, suspension of budget-making process
- State blames underdevelopment for insecurity in 23 counties
